Loading organizations...
Loading organizations...
Biopharmaceutical company developing cell therapies for oncology.
IASO Biotherapeutics has raised $241.9M across 3 funding rounds.
IASO Biotherapeutics has raised $241.9M in total across 3 funding rounds.
IASO Biotherapeutics has raised $241.9M in total across 3 funding rounds.
IASO Biotherapeutics's investors include Efung Capital, Hongcheng Investment, Housen Care Brothers, Nanjing Jiangbei New Area State-owned Asset Management, Shanghai Guoxin Investment & Development, Shanghai Waigaoqiao Free Trade Zone Group, Wei Ying, CCB International, China Everbright, Plaisance Capital Management.
IASO Biotherapeutics has raised $241.9M across 3 funding rounds. Most recently, it raised $73.9M Series C in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 18, 2023 | $73.9M Series C | Efung Capital, Hongcheng Investment, Housen Care Brothers, Nanjing Jiangbei New Area State-owned Asset Management, Shanghai Guoxin Investment & Development, Shanghai Waigaoqiao Free Trade Zone Group | |
| Sep 16, 2021 | $108.0M Series C | Wei Ying | CCB International, China Everbright, Plaisance Capital Management |
| Mar 24, 2020 | $60.0M Series B |